The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis

BACKGROUND: The role of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) is not clear in early‐stage nonsmall‐cell lung cancer (NSCLC) patients. This meta‐analysis aims to compare the efficacy and safety of EGFR‐TKIs as adjuvant therapy with chemotherapy or placebo in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chutong, Hu, Fengling, Chu, Hongling, Ren, Peng, Ma, Shanwu, Wang, Jingdi, Bai, Jie, Han, Xuan, Ma, Shaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017245/
https://www.ncbi.nlm.nih.gov/pubmed/33660941
http://dx.doi.org/10.1111/1759-7714.13874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017245/
https://www.ncbi.nlm.nih.gov/pubmed/33660941
http://dx.doi.org/10.1111/1759-7714.13874

Ejemplares similares